Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-09
B
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Baha’a Jabali’s research focuses on the discovery and development of novel kinase inhibitors for cancer treatment. His work has led to the identification of selective aurora kinase B inhibitors, including the first orally active compound of this class, and dual RET/TRKA inhibitors. Jabali has also investigated quinazoline-based dual RET/Aurora B inhibitors specifically for non-small cell lung cancer.
His publications include studies on the synthesis and characterization of metal complexes with anti-inflammatory drugs, and a perspective on macrocycles for targeting the kinome. Jabali has a h-index of 4 across 6 publications, with over 100 citations. He has collaborated with researchers at the University of Arkansas for Medical Sciences, including Brendan Frett, Baku Acharya, and Maha Hanafi, on multiple shared publications.
Metrics
- h-index: 4
- Publications: 6
- Citations: 113
Positions
-
Ph.D. publications 2023–2026University of Arkansas for Medical Sciences Institution web page
Selected Publications
-
Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer (2026)
-
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
-
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors (2024)
-
Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules (2023)
Collaboration Network
Top Collaborators
Brendan Frett
University of Arkansas for Medical Sciences
4 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
Baku Acharya
University of Arkansas for Medical Sciences
3 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
Maha Hanafi
Cairo University
3 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer
Debasmita Saha
Sanford Burnham Prebys Medical Discovery Institute (US)
2 shared publications
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
Daniel W. Armstrong
University of Arkansas for Medical Sciences
2 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
Alan Herrera-Rueda
University of Arkansas for Medical Sciences
1 shared publication
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
Naga Rajiv Lakkaniga
Indian Institute of Technology Dhanbad (IN)
1 shared publication
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
Noemi Garcia Garcia
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
Katie R. Ryan
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
Phuc Tran
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Marialuisa Moccia
University of Naples Federico II (IT)
1 shared publication
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Xiuqi Wang
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Annalisa Brescia
University of Naples Federico II (IT)
1 shared publication
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Giorgia Federico
University of Naples Federico II (IT)
1 shared publication
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Gunaganti Naresh
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Similar Researchers
Based on overlapping research topics
Anupreet Kharbanda
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Discovery
Structure-Activity Relationship
Erica Lane Smith
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Discovery
Receptor Mechanisms and Signaling
Amal M. Shoeib
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Receptor Mechanisms and Signaling
Structure-Activity Relationship
Emily Kanwischer
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Discovery
Cancer-related molecular mechanisms research
Gavin Hargrove
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research
Daniel Armstrong
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research